";s:4:"text";s:4633:"]To report SUSPECTED ADVERSE REACTIONS, contact TruPharma, LLC at 1-813-444-6299 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.We comply with the HONcode standard for trustworthy health information - For this medicine, the following should be considered:Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. When you are receiving this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. Unstable angina: 5 mg IV bolus x3 q2min f/b 2 to 5 mg hourly titrated to min HR of 55 to 60 BPM or min systolic BP of 80 . toprol. The subject was in fair health and had a regular exercise routine, mostly moderate, but including swimming approximately 75 minutes per week. Musculoskeletal pain, blurred vision, and tinnitus have also been reported.There have been rare reports of reversible alopecia, agranulocytosis, and dry eyes. Note: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Metoprolol tartrate USP is (±)-1-(Isopropylamino)-3-[Metoprolol tartrate USP is a white, practically odorless, crystalline powder with a molecular weight of 684.82. Treatment with intravenous metoprolol can be initiated as soon as the patient's clinical condition allows (see Hypersensitivity to metoprolol and related derivatives, or to any of the excipients; hypersensitivity to other beta blockers (cross sensitivity between beta blockers can occur).Metoprolol is contraindicated in patients with a heart rate <45 beats/min; second- and third-degree heart block; significant first-degree heart block (P-R interval ≥0.24 sec); systolic blood pressure <100 mmHg; or moderate-to-severe cardiac failure (see Beta blockers, like metoprolol, can cause depression of myocardial contractility and may precipitate heart failure and cardiogenic shock. To report SUSPECTED ADVERSE REACTIONS, contact Almaject, Inc. at 1-866-770-3024 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.Protect from light and heat.